NEW YORK - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from Covid-19 booster shots in a market that could rival the $6 billion in annual sales for flu vaccines for years to come, analysts and healthcare investors say.
Pfizer, along with its German partner BioNTech , and Moderna have together locked up over $60 billion in sales of the shots just in 2021 and 2022. The agreements include supply of the initial two doses of their vaccines as well as billions of dollars in potential boosters for wealthy nations. As a result, it is far from clear how many people will need boosters, and how often. The profit potential of booster shots may be limited by the number of competitors who enter the market. In addition, some scientists question whether there is enough evidence that boosters are needed, particularly for younger, healthy people. The World Health Organization has asked governments to hold off on booster shots until more people worldwide receive their initial doses.
Flu vaccination rates in developed countries have settled at around 50% of the population, and COVID boosters would likely follow a similar pattern if approved widely, said Atlantic Equities analyst Steve Chesney.
I still can't believe that real account manager exist I am so happy trading with shantelll_142 i never took her serious because I taught she was a scam like others ,until my first withdrawal of R60,000 within just one week of trading! I am so grateful 🤗🤗
What a wonderful man. Thanks alot Albert_Kason my Friend; I have just recieved the $12,000 profit return now inside my LUNO wallet. I believe you now 💯SIR... YOU ARE THE BEST👌🤞✅☑️✅